Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Is there a role for surgical debulking for patients with stage IV lung sarcomatoid carcinoma?
Related Questions
How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?
For patients with stage I NSCLC, do you use RiskReveal, and if so, how do you use it to guide treatment?
What high-risk features for stage I NSCLC would lead you to consider adjuvant osimertinib?
When do you recommend incorporating HER2 testing into the diagnostic pathway for tumor types where HER2 overexpression is not commonly assessed?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
How would you approach treatment for EGFR-mutant NSCLC with acquired ERBB2 mutation and amplification as resistance to prior osimertinib-based therapy?
How would you approach adjuvant therapy for patients with mucinous lung adenocarcinoma with an intestinal phenotype?
How do you transition between TKIs for stage IV NSCLC with actionable mutations?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Is there any data supporting the use of osimertinib in patients with L858R-mutated lung cancer who had a durable response to prior EGFR TKI therapy, and who progressed 1-2 years after discontinuation of other EGFR inhibitors?
